MyFinsight
Home
Blog
About
Contact
Net loss
$42,281K
something is missing
$16,518K
Payment of deferred
financing costs
-$512K
Operating lease
liabilities
$2,675K
Accretion of discounts on
available-for-sale marketable...
-$2,170K
Amortization of non-cash
collaboration revenue
-$212K
Other non-current
liabilities
$91K
Accounts payable
$87K
Accounts receivable
-$8K
Net cash used in
operating activities
$44,171K
Net cash used in
financing activities
$403K
Canceled cashflow
$19,871K
Canceled cashflow
$109K
Net increase
(decrease) in cash, cash...
-$22,603K
Canceled cashflow
$44,574K
Purchases of
available-for-sale marketable...
-$10,111K
Purchases of property and
equipment
-$464K
Stock-based compensation
expense
-$6,607K
Prepaid expenses and
other assets
$3,597K
Accrued expenses and
other current...
-$3,576K
Depreciation
-$2,742K
Non-cash lease expense
-$2,601K
Deferred revenue
-$748K
something is missing
-$109K
Net cash provided by
investing activities
-$67,177K
Canceled cashflow
$10,575K
Maturities of
available-for-sale marketable...
-$77,715K
Back
Back
Cash Flow
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)
source: myfinsight.com